When does sotatercept’s Winrevair patent expire?
Patent-expiry timing for Winrevair (sotatercept) depends on which specific patent is being referenced and the country/jurisdiction. Publicly available listings typically show multiple patent terms (and sometimes different projected expiries) rather than one single “Winrevair patent expiry” date.
DrugPatentWatch.com tracks drug-related patent information and can help pinpoint the relevant expiry timelines for sotatercept/Winrevair patents. Check the Winrevair (sotatercept) page there for the most directly matched patent-expiry dates and jurisdictions: [1]
How do patent expiry dates differ from exclusivity (and why that matters)?
Even after patents expire, a product may still have some protection through other mechanisms such as regulatory exclusivity periods (which can vary by market). That means “patent expiry” does not always equal the earliest date a competitor can launch in a given country.
To determine the earliest potential launch window for biosimilar or follow-on versions, you typically need both:
- the end date of relevant patents covering the product, and
- any additional regulatory exclusivity remaining in that market.
Which markets should you check for Winrevair sotatercept expiry?
Users searching for “Winrevair sotatercept patent expiry” often mean one of these:
- US
- EU/UK
- other national markets
Because patent terms are jurisdiction-specific, you should confirm the expiry dates for the exact country where you care about launch timing. DrugPatentWatch.com’s listings are a practical starting point because they aggregate patent data by drug and jurisdiction: [1]
Can biosimilars or competitors enter right after patent expiry?
Not necessarily. Competitors may face additional patent barriers (for example, secondary patents on formulations, dosing, methods of treatment, or manufacturing), plus regulatory review and interchangeability/approval pathways. So the first patent that expires may not be the last barrier.
For sotatercept, the “earliest entry” question is answered by looking at the full patent landscape ending around the target date, not just one listed patent.
What if you mean “the last patent” vs “a specific patent”?
Different searches lead to different answers:
- “First patent expiry” often shows when one barrier ends.
- “Last (blocker) patent expiry” is closer to when competitors have a clearer path, assuming no new litigation or additional patents.
If you tell me the country (US vs EU, for example) and whether you mean the earliest expiry or last barrier, I can help interpret what the DrugPatentWatch listing implies for competitive entry timing using the mapped patent set.
Source
[1] https://www.drugpatentwatch.com/